Top Tweets for #OneSourceSpecialty

9 days ago

#JustIn | #OnesourceSpecialty Says: Delay in #DRL’s #Semaglutide commercial supplies has no material impact on operations. Co remains committed to its long-standing partnership with DRL Has sufficient demand from other customers, including Canada, with full capacity utilisation

9 days ago

#JustIn | #DRL says certain batches of semaglutide are out of specification due to an #API issue; commercial supplies will be delayed until the issue is resolved

CNBCTV18Live's tweet photo. #JustIn | #DRL says certain batches of semaglutide are out of specification due to an #API issue; commercial supplies will be delayed until the issue is resolved https://t.co/vh7VpL2OEQ

1

11

1

25K

0

15

1

2

25K

2 months ago

#4QWithCNBCTV18 | #OnesourceSpecialty Sees Sequential Recovery In Q4 MD & CEO, Neeraj Sharma To @CNBCTV18News - Cost of input materials have been impacted due to #WestAsia crisis - Sticking to FY28 guidance of Rs 40,000 cr revenue & 40% margin @ekta_batra @vinnii_motiwala @sonalbhutra #CNBCTV18Market #Semaglutide Watch: https://t.co/jgRC4hOPDQ

1

3

1

3K

2 months ago

#OneSourceSpecialty Pharma shares fall as #Q4 profit plunges 95%, margins halve @GareemaBangad https://t.co/wpcMRodxlH

0

6

0

1

4K

2 months ago

#4QWithCNBCTV18 | #OnesourceSpecialty reports its Q4 results: --Net Profit At ₹4.6 Cr Vs ₹98.5 Cr (YoY) --Revenue Up 1% At ₹428.2 Cr Vs ₹426 Cr (YoY) --EBITDA Down 50% At ₹92 Cr Vs ₹182 Cr (YoY) --Margin At 21.5% Vs 42.7% (YoY) --Loss Before Tax At ₹3 Cr Vs Profit Of ₹84 Cr (YoY)

CNBCTV18Live's tweet photo. #4QWithCNBCTV18 | #OnesourceSpecialty reports its Q4 results:

--Net Profit At ₹4.6 Cr Vs ₹98.5 Cr (YoY)

--Revenue Up 1% At ₹428.2 Cr Vs ₹426 Cr (YoY)

--EBITDA Down 50% At ₹92 Cr Vs ₹182 Cr (YoY)

--Margin At 21.5% Vs 42.7% (YoY)

--Loss Before Tax At ₹3 Cr Vs Profit Of ₹84 Cr (YoY)

1

28

2

1

5K

3 months ago

#VolumeBuzzers Yesterday Pharma👇🏻 #OnesourceSpecialty #ShailyEngineering #PiramalPharma #DrReddys Auto👇🏻 #AshokLeyland #TVSMotor #M&M @hormaz_fatakia #CNBCTV18Market #MnM

0

4

0

2K

3 months ago

D-Street Chatter | Strong pullback on global risk-on ahead of crucial US-Iran talks - Flows mixed with a positive bias towards financials - #OnesourceSpecialty #KajariaCeramics #Mastek #LGElectronics #BPCL #UnionBank buzzing in trade @nimeshscnbc #CNBCTV18Market

1

5

3

1

4K

5 months ago

What's Triggering The Sharp Correction In CDMO Stocks? - Weak Q3results, muted topline guidance - Inventory de-stocking in key products - China+1 Shift - Regulatory delays @ekta_batra puts the moves into perspective #Pharma #BlueJet #Syngene #Cohance #OnesourceSpecialty #CNBCTV18Market

1

15

4

14

5K

5 months ago

D-Street Chatter | Market Under Pressure Dragged By Tech And Metal Stocks * Aggressive selling in large cap tech stocks * Nifty support around 25,450 crucial * #NazaraTech #ElinElectronics #OnesourceSpecialty #OswalChemicals buzzing in trade @nimeshscnbc #CNBCTV18Market #CNBCTV18News

0

3

2

0

2K

6 months ago

#3QWithCNBCTV18 | A Weak #Q3FY26 For #OnesourceSpecialty CEO & MD, Neeraj Sharma to @CNBCTV18News - This is going to be a transition year for the company - Investing almost `700 cr in new capex #CNBCTV18Market @_prashantnair @Nigel__DSouza @Reematendulkar

0

1

0

1K

7 months ago

#OnesourceSpecialty In Focus #Semaglutide Goes Off-Patent In Canada In Jan 2026 CEO & MD, Neeraj Sharma to @CNBCTV18News - India is turning out to be a significant market for GLP-1 - Opportunity for #Semaglutide in Canada is massive #CNBCTV18Market @ek @ekta_batra & @vinnii_motiwala Watch: https://t.co/PPA6AqUBRe

1

3

0

2

2K

Mint

@livemint

about 1 year ago

#OnesourceSpecialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with expanding capacity, strong global clients, and rising revenue from FY26 onwards. https://t.co/drNxTYzvdD

3

1

0

1

1K